MA
VRTX icon

MONECO Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

MONECO Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-514
Closed -$201K – 533
2025
Q3 		$201K Sell
514
-105
-17% -$43.9K 0.02% 486
2025
Q2 		$276K Hold
619
– – 0.03% 397
2025
Q1 		$300K Buy
+619
New +$288K 0.03% 361

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

MONECO Advisors's VRTX Position: Q4 2025 in Review

MONECO Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 514 shares — an estimated $201K sold.

MONECO Advisors first reported a position in VRTX in Q1 2025 and held it in 3 quarters. The position peaked at $300K in Q1 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • MONECO Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • MONECO Advisors sold 514 Vertex Pharmaceuticals shares in Q4 2025, an estimated $201K.
  • MONECO Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • MONECO Advisors's Vertex Pharmaceuticals position peaked at $300K in Q1 2025.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on MONECO Advisors's 13F filing for Q4 2025, filed 4 Feb 2026.